Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
September 02, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral...
Adamis Pharmaceuticals logo
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
August 24, 2021 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company’s Chief Accounting...
Adamis Pharmaceuticals logo
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
August 19, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment for COVID-19...
Adamis Pharmaceuticals logo
Adamis Announces Agreement to Sell Portion of US Compounding Business
August 04, 2021 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a significant portion of the...
Adamis Pharmaceuticals logo
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
June 11, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of...
Adamis Pharmaceuticals logo
Adamis Provides Update on ZIMHI™
June 09, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s...
Adamis Pharmaceuticals logo
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
June 07, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Business Update
June 01, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
May 28, 2021 16:04 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
May 17, 2021 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be...